Clinical AdvancementsArrowhead's lead program, ARO-ATXN2 for spinocerebellar ataxia 2, is supported by promising mouse data showing significant reductions in target proteins.
Pipeline DevelopmentThe plozasiran pipeline-in-a-drug strategy is underscored by positive Phase III PALISADE study results in familial chylomicronemia syndrome.
Strategic FinancingArrowhead Pharmaceuticals announced securing $500M strategic financing facility with flexible 7-year repayment structure, which supports its aggressive pipeline expansion.